Polysubstance Use in Pregnancy: Surveillance, Interventions, and Next Steps
- PMID: 37552850
- PMCID: PMC10558011
- DOI: 10.1089/jwh.2023.0341
Polysubstance Use in Pregnancy: Surveillance, Interventions, and Next Steps
Abstract
Substance use during pregnancy increases risk for a wide range of adverse maternal and neonatal health outcomes. Polysubstance use is common among people who use substances during pregnancy; however, the risks of combined substance exposures during pregnancy are poorly understood. In this report, we provide an overview of the activities of the Centers for Disease Control and Prevention (CDC) and partners and identified gaps related to (1) surveillance, (2) routine screening, and (3) prevention of polysubstance use during pregnancy. Efforts by CDC and other partners to reduce polysubstance use during pregnancy can improve the health of pregnant people and their infants and children.
Keywords: alcohol; opioids; polysubstance use; pregnancy; prenatal substance exposure; smoking.
References
-
- Substance Abuse and Mental Health Services Administration. Results from the 2020 National Survey on Drug Use and Health: Detailed Tables. Substance Abuse and Mental Health Services Administration: Rockville, MD; 2021.
-
- Qato DM, Zhang C, Gandhi AB, et al. Co-use of alcohol, tobacco, and licit and illicit controlled substances among pregnant and non-pregnant women in the United States: Findings from 2006 to 2014 National Survey on Drug Use and Health (NSDUH) data. Drug Alcohol Depend 2020; 206:107729; doi: 10.1016/j.drugalcdep.2019.107729 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
